secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0000950142-23-000411
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q4 rev $27M (+8.3% seq); FY22 rev $97.9M vs $130.6M; guides 2023 flat-to-mod growth
--------------------------------------------------------------------------------

- Q4 2022 GAAP revenue $27.0M; core product/service rev $26.8M, up 8.3% sequentially.
- Full year GAAP revenue $97.9M (down from $130.6M in 2021); core rev $94.5M vs $111.6M.
- Q4 product margin GAAP 40.9% (+620 bps seq), non-GAAP 52.9% (+520 bps); opex down 16% seq to $32.3M.
- 2023 guidance: flat-to-moderate core rev growth; GAAP opex ~$118-123M (20% reduction); Q4 GAAP gross margin 52-55%.
- Cash $165.8M at year-end; expects positive free cash flow by end of 2024; restructuring to cut >$30M opex annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/eh230318897_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-23-000411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer